• 

  France, UK Insurers Say They Won’t Cover Alzheimer’s Drug Leqembi
• 

  OP-ED: Why UK Health Insurers Were Right to Reject New Alzheimer’s Drugs
• 

  So Far, Australia Approves Only 1 of the 2 New Alzheimer’s ‘Mab’ Drugs
• 

  No Kisunla in Europe: Regulators Reject Lilly’s Alzheimer’s ‘Mab’ Drug
• 

  Leqembi Vs. Kisunla: An Alzheimer’s Drug Point-by-Point Comparison
• 

  UK Insurance Didn’t Want to Cover Leqembi. Now, It Says It Won’t Cover Kisunla, Either
• 

  8/11 of the Doctors Who Advised on Kisunla Approval Had Conflicts of Interest
• 

  7 Things to Know About New Alzheimer’s Drug Kisunla
• 

  FDA Approves New Alzheimer’s Drug Kisunla (Donanemab)
• 

  FDA Advisory Committee Recommends Approval of New Alzheimer’s Drug
• 

  Alzheimer’s Drug Decision Pushed: FDA Slows Down on Donanemab
• 

  Alzheimer’s Drugs and ARIA: Leqembi ‘Brain Bleeds’ Side Effect, Explained
• 

  An Army Vet’s 23&Me Test Inspired Him to Join a Clinical Trial. There, He Learned He Had Early Signs of Alzheimer’s
• 

  OP-ED: New Alzheimer’s Drugs Don’t Deserve the Hype
• 

  The Next Anti-Amyloid in the Alzheimer’s Pipeline: Donanemab

12Next